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Introduction
Both viral and nonviral vectors are currently being developed for gene therapy. The transfection of plasmid DNA complexed with liposome carrier molecules into cells is simple and of low cytotoxicity, but several factors limit DNA delivery by this approach. These include comparatively poor transfection efficiency, nontargeted delivery and transient transgene expression. Alternatively, viral vectors offer highly efficient DNA delivery and have been engineered to target specific cellular receptors. Adenoviral vectors have been shown to transduce cells efficiently and can be purified to the high titres applicable for successful in vivo gene therapy. However, adenovirus vectors are limited by transient transgene expression and intrinsic immunogenicity. 1 Retroviral gene transfer offers more stable gene delivery as the retrovirus integrates into the host genome. Recent advances in retroviral biology have further increased the suitability of retroviral vectors for use in clinical trials. These developments include safety features such as self-inactivating vectors, which once integrated leave the viral LTR promoter defective thereby avoiding promoter/enhancer insertional mutagenesis. 2 Retrovirus infection is restricted to cells which express the appropriate receptor molecules for virus attachment and novel virus pseudotypes have been engineered with envelopes capable of recognising specific cell receptors. 3 Retroviral envelope pseudotyping is also employed to overcome the relatively low viral titres which are a major barrier to in vivo use. For example virions peudotyped with the envelope of vesicular stomatitis virus (VSV-G) can be concentrated by high speed centrifugation. 4 More recently retroviruses resistant to complement inactivation by human serum 5 and virus producer cells with enhanced retrovirus genome expression using an efficient cytomegalovirus (CMV) promoter within the virus LTR have also enabled increases in virus titre. 6, 7 Further methods used to improve virus titre include ultrafiltration using low speed centrifugation and hollow fibre filtration. 8, 9 Virus infectivity can be enhanced several-fold by the use of positively charged molecules such as polybrene or DEAE dextran. These compounds complex with the virus envelope and target the cell wall thereby reducing the repulsive negative charges, which are believed to inhibit virus attachment to the target cell receptors. 10 The use of these agents is limited in vivo by both their toxicity and lack of efficacy. Recently several authors have demonstrated in vitro that complexing virus particles with cationic amphiphiles can enhance virus infection above that observed in the presence of polybrene. [11] [12] [13] Such amphiphiles have been used for several years to mediate DNA transfer to cells, albeit at a lower efficiency than viruses. They include cationic liposomes which are lamellar vesicles and a variety of cationic compounds in either linear or branched form with the ability to complex negatively charged molecules. 14, 15 In this study we have screened a wide range of cationic agents in search of the most effective and nontoxic compounds able to enhance retrovirus titre. We show that virus titres of 1 × 10 9 IU/ml can be reached in vitro by combining virus titre enhancement with cationic amphiphiles together with concentration of virus particles by ultrafiltration. Furthermore, in an in vivo model of liver transduction, we demonstrate that the addition of cationic amphiphiles to retroviral vectors before intraportal injection increases the efficiency of hepatocyte transduction five-fold without any increase in toxicity.
Results
To determine the effects of cationic agents on retroviral titre, several commercial and noncommercial cationic liposomes, lipopolyamines and cationic polymers (listed in Table 1 ) were investigated at a range of concentrations from 0.025-30 g/ml in combination with ecotropic and amphotropic virus supernatants. The virosomes thus generated by each combination were titred on NIH3T3 cells and the level of infection was compared with that obtained with polybrene. In addition, the effects on cellular morphology and survival of NIH 3T3 cells were examined.
Enhancement of retroviral transduction by cationic agents
Virosomes were generated with ecotropic viruses produced by GPE+86LHL cells and amphotropic viruses from PA317HyTk MLV cells. Each virus was used to infect NIH3T3 cells for 24 h and the resulting hygromycin B resistant colonies were scored to determine the optimum virosome complex combination for highest virus titre.
Virus titres for each respective pseudotype without cationic agents were approximately five-fold lower than in the presence of polybrene. Ecotropic viruses exhibited at least a 20-fold greater level of transduction than their Table 1 showed a variable and concentration-dependent ability to transduce NIH3T3 cells. Table 2 shows the concentration of each cationic agent required for maximum virus titre in comparison to that using virus alone. Many of the agents tested improved transduction levels significantly above those observed with virus only or with viruses in combination with polybrene. Of the cationic polymers, the most effective was PEI. Although cytotoxicity was observed with PEI at 5 g/ml (Table 1) , much lower concentrations were required to enhance ecotropic and amphotropic virus transduction by 17-and 19-fold, respectively ( Table 2) . Several cationic liposomes also improved virus transduction substantially, especially LipofectAMINE liposomes and those formulated from the noncommercial cationic amphiphile N 1 -cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine CDAN (see Materials and methods), 16 which stimulated ecotropic retroviral transduction 20-and 23-fold, respectively. Intriguingly, some cationic liposomes were able to enhance only one virus pseudotype and not the other. For instance, DMRIE C liposomes and lipid 67 containing liposomes, 17 were able to enhance infectivity of ecotropic viruses marginally higher than polybrene, whereas no increase was observed using amphotropic virions. By contrast, Tfx50 liposomes were only able to enhance amphotropic virions and not ecotropic particles.
Generally, a higher cationic agent concentration was needed to reach maximum titre for amphotropic than for ecotropic viruses (Table 2) . Of all the cationic agents tested, lipopolyamine DOGS and cationic liposomes formulated from CDAN gave the best virus titre enhancement of 36-and 23-fold, respectively, for ecotropic virus, and 24-and 21-fold, respectively, for amphotropic virus. The concentration of DOGS required to reach these titres for each virus pseudotype was higher than the liposome concentration of CDAN (Table 2) . However, DOGS produced the highest virus titres overall (Figure 1a and b). We also used amphotropic virus/DOGS complexes on the HepG2 liver cancer cell line to investigate whether a liver tumour cell line could be more efficiently infected using a concentration of 1.75 g/ml of DOGS. This was found to enhance the infection of the HepG2 cells by amphotropic retrovirus five-fold over that observed with a polybrene/virus combination. These data encouraged us to investigate further possible cytotoxic effects of each cationic agent. 
Survival of NIH3T3 cells in the presence of virosome complexes
To test the concentration of cationic agent which could enhance virus titre without cytotoxicity, cells were exposed to a range of cationic agent concentrations complexed with virus particles for 24 h (the length of time chosen to infect cells by retroviral particles). They were then examined morphologically and by a clonal assay for cell survival. Cytotoxicity was determined by the reduction in percentage survival of colony-forming units (c.f.u./ml) in comparison with mock-treated control cells. Table 1 shows the concentration of cationic agents which reduced cell survival to 50% or less. Viruses alone showed no cytotoxicity. In general, virosome complexes formed with 1.75 g/ml or less cationic agent typically showed little or no cytotoxicity. Exceptions to this rule were cationic liposomes formulated from cationic lipids 3-aza-N 1 -cholesteryloxycarbonylhexane-1,6-diamine ACHx and 4-aza-N 1 -cholesteryloxycarbonyloctane-1,8-diamine ACO, 16 as well as polycationic polymer PEI. The last reduced cloning efficiency to slightly below 90%. At 5 g/ml several of the generated virosomes reduced cell survival to approximately 50% or below (Table 1 ) (shown in parallel by a fall in transduction levels). In contrast, several cationic agents produced no cytotoxic effects at this concentration; the least toxic being DOGS. CDAN containing liposomes also promoted high virus titres with both virus pseudotypes at concentrations well below those inducing cytotoxicity.
Optimisation of virus titre by combining cationic agent effects with virus concentration
To reach maximum virus titre virus particles were first concentrated by ultrafiltration and then complexed with DOGS at 1.75 g/ml. Virus producer cells TELCeB/ MOF-1 and TELCeB/AL-7, generating ecotropic and amphotropic virions, respectively, which encode the lacZ gene were titred at 1 ± 10 7 IU/ml (in the presence of polybrene). By complexing with DOGS these cells each produced virus titres of 1 × 10 8 IU/ml (Figure 1a and b). Ten-fold concentrated ecotropic virus stock (by ultrafiltration) increased the virus titre, in the presence of polybrene, to 1 × 10 8 IU/ml while a virus titre of nearly 1 × 10 9 IU/ml without observable cytotoxicity was reached by complexing the concentrated virus with DOGS. Application of this procedure with amphotropic virus led to titres of approximately 3 × 10 8 IU/ml. These data encouraged us to investigate the efficiency of virus complexed with DOGS for in vivo gene delivery.
Transduction of rat liver in vivo by retroviral vectors Animals were transduced in vivo by portal vein injection 24 h following partial hepatectomy or sham hepatectomy, all animals were killed at day 11. The amphotropic retroviral vector from TELCeB/AL-7 cells was used both with and without the addition of cationic agents.
Animals which had received a sham hepatectomy 24 hrs before retroviral transduction showed a very low level of hepatic ␤-galactosidase expression in their livers following transfection with either the TELCeB/AL-7 virus alone, 0.04 ± 0.04% (n = 4) or the TELCeB/AL-7 virus and DOGS, 0.05 ± 0.03% (n = 4).
Animals which had received a partial hepatectomy 24 hrs before transduction had 5.2 ± 2.1% (n = 7) of their hepatocytes expressing nuclear localised ␤-galatosidase.
The hepatocyte transduction efficiency was enhanced to 27.4 ± 5.8% (n = 7) by combining the TELCeB/AL-7 retroviral supernatant with DOGS before infusion and to 10.2 ± 2.8% (n = 8) by combining the TELCeB/AL-7 retroviral supernatant with CDAN containing liposomes before use. Representative photomicrographs of X-galstained frozen sections of rat liver from day 11 are shown in Figure 2 . ␤-Galactosidase transgene expression was also sought in the heart, lung, testes, skeletal muscle and brain of all animals in each group but was not detected in any animal.
Following administration of the retrovirus or retroviral/cationic agent complexes to either normal animals or animals that had received a partial hepatectomy 24 h earlier, there was no mortality or signs of distress observed. Histological sections of liver at the time of death showed no evidence of either ongoing hepatitis or recent hepatocyte necrosis.
Discussion
We have studied several novel retrovirus/cationic agent combinations with the aim of enhancing both in vitro and in vivo retrovirus infectivity. Cationic agent concentrations were optimised for enhancement of viral transduction and minimum cytotoxicity. DOGS complexed with either ecotropic or amphotropic viruses gave the largest enhancements in viral titre in comparison to all the other cationic agents tested. Several other virus/cationic agent combinations showed useful improvements in transduction levels of the NIH3T3 indicator cell line.
Ideally the optimal concentration should allow complexing of all available viral particles while not causing cytotoxicity. Interestingly, the cytotoxicity of each cationic agent did not prove to be the limiting factor for transduction efficiency. The optimum concentration for each cationic agent at which the maximum increase in transduction was observed, was always less than the cytotoxicity threshold. Therefore, the efficacy of each cationic agent appeared to depend directly upon its ability to enhance virus-cell interaction rather than upon a reduction in cell survival. DOGS enhanced virus titre by almost one order of magnitude over polybrene. In addition, DOGS showed only a partial fall in virus titre enhancement over the optimum of 1.75 g/ml and 5 g/ml required for ecotropic and amphotropic virus, respectively. DOGS appeared effective in promoting efficient virus infection up to a cytotoxic threshold of 40 g/ml which was significantly higher than the majority of the other cationic agents tested as measured by clonal assay and cellular morphology. Using TELCeB/MOF-1 and TELCeB/AL-7 cells, to generate ecotropic and amphotropic viruses respectively, encoding the lacZ vector, DOGS enabled titres to reach 1 × 10 8 IU/ml without concentration. DOGS was therefore considered an ideal candidate cationic agent for in vivo use. Indeed, DOGS was able significantly to enhance infectivity in vivo without any animal mortality or observed distress. In addition, no hepatocyte necrosis was observed following histological analysis of liver sections. The virosome complexes appeared to be relatively stable in animal serum.
Possible mechanisms of retrovirus titre enhancement in the presence of cationic agents include: more efficient cell binding and entry of the virus, increased transport of the reverse-transcribed viral DNA to the nucleus of the infected cell or prolonged virus half-life. The transduction efficiencies exhibited by the virosome complexes appeared to vary widely. For instance, Tfx50 liposomes were unable to enhance ecotropic virus transduction whilst enhancing amphotropic virus infection six-fold. By contrast, most cationic liposome stimulation was more pronounced on the ecotropic virus. Perhaps the ability of the cationic agent to adapt to the surface conformation of the virus envelope determines the ability of any given cationic agent to enhance virus infection. That is to say, the more efficiently the cationic agent may coat the virus particle, the more effectively the repulsive forces between virus particle and cell membrane are neutralised, thus allowing the virus to enter the cells more easily. In support of this, DEAE dextran is known to be capable of neutralising the repulsive forces between the virus particle and cell membrane through the formation of large cationic polymer structures sandwiched between the virus and the cells. 10 Hence, DOGS appears to be structurally best suited for interaction with the envelopes of both viral pseudotypes and therefore for the efficient regulation of the repulsive forces between virus particles and cell membranes.
Complexing retrovirus with nontoxic cationic agents is a useful method to improve virus titres as exemplified by the increase in infectivity of ecotropic virus by one order of magnitude when combined with DOGS over the infectivity observed when using polybrene. The combination of this approach with ultrafiltration of the virus enhances virus titre further up to about 1 × 10 9 IU/ml. Ultrafiltration is probably less harsh than ultracentrifugation. This combination could also improve infectivity in vivo, however, the volumes of virus supernatant required for in vivo application would require large-scale culture and concentration procedures. DOGS, which was able to improve the transduction of NIH3T3 cells by amphotropic retroviruses also improved the infectivity of the liver tumour cell line HePG2 by five-fold over that observed using polybrene. This suggested that virosome complexes could be tested in vivo on the liver. The liver was chosen as an in vivo target for nonconcentrated virosome complexes for several reasons. The liver is an important target for gene therapy, it is the major metabolic organ and a site of metastatic cancer spread. The model of intraportal injection of retrovirus 24 h following partial hepatectomy is well characterised and repeatable. 18, 19 Using this model, if retroviral vectors are injected intraportally they transduce approximately 5% of hepatocytes. 20 However, it is known that at this time 30-45% of the liver hepatocytes are in S phase of the cell cycle 21 and are therefore potential targets for retroviral vectors. We therefore hypothesised that if the titre of the retroviral vector could be increased then the number of transduced hepatocytes could also be increased following a single injection of vector. Polybrene is commonly used to increase the titre of retroviral vectors in vitro but has not been shown to be effective in vivo. 22 We have demonstrated that the in vivo transduction efficiency of retroviral vectors can be increased five-fold by the simple addition of a lipopolyamine or cationic liposomes to the retroviral supernatant before their use. This process was well tolerated by the recipient animals which had no excess of morbidity or mortality over ani- mals receiving the retroviral supernatant alone. Importantly the addition of these cationic agents did not broaden the tissue range beyond that seen with retroviruses alone.
Recent work has shown that the liver can be primed to accept retroviral vectors without performing a partial hepatectomy by administering growth factors 23 or transducing the liver with the urokinase gene. 24 These methods are more clinically acceptable than partial hepatectomy, but because the liver remains intact, the number of target cells is increased, consequently the titre of the retroviral vector used when utilising these techniques may have greater importance. Although the virus titres obtained by these procedures are still somewhat lower than those observed with adenovirus, this study has shown that titres of integrative retrovirus vectors may be increased safely to levels more closely suited for use in gene therapy protocols with the advantage of no cytotoxic effects. In future experiments we aim to apply concentrated virus stocks from large-scale culture concentrated by hollow fibre filtration to in vivo delivery in order to increase further the number of hepatocytes expressing the ␤-galactosidase gene.
Materials and methods
Retroviruses Retrovirus particles were generated by the packaging cells lines GPE+86 LHL and PA317 tgLS[+]HyTK producing ecotropic and amphotropic virions, respectively. Each encode the hygromycin phosphotransferase gene and confer resistance to the phosphotransferase inhibitor hygromycin B (Calbiochem, CA, USA) on infected cells. The cell lines TELCeB/AL-7 and TELCeB/MOF-1 were used to produce amphotropic and ecotropic particles, respectively, and encode a LacZ gene which expresses nuclear localising ␤-galactosidase. Each cell line was used to infect NIH3T3 cells to determine virus titres using the cationic polymer polybrene as the transduction-enhancing agent as previously described. 25 Generation of high titre retrovirus stocks High titres of amphotropic and ecotropic retrovirus stocks were produced. Virus producer cells were grown in DMEM supplemented with 10% foetal calf serum at 37°C. To prepare viruses, cells were grown to confluency and refed with fresh serum containing medium overnight. The following day virus containing supernatants were harvested and filtered through 0.8 m filters for determination of retrovirus titre and helper virus assay. Helper virus assays were performed on NIH3T3 cells as previously described, using serial dilutions of virus. 25 Briefly, for virus titration 4 × 10 4 NIH3T3 cells were seeded into each well of 12-well culture dishes and incubated overnight at 37°C. Cells were infected with retroviruses for 24 h followed by a 24-h period to allow for transgene expression. Titres were analysed either by using a ␤-galactosidase enzymatic assay or by seeding cells at clonal density on to 60 mm dishes in hygromycin B selection to score colonies resistant to this selective agent. In the presence of polybrene (Sigma, Poole, UK) a titre of 1 × 10 7 c.f.u./ml and 3 × 10 6 c.f.u./ml was established for GPE+86 LHL and PA317 tgLS[+]HyTK cells, respectively, and 1 × 10 7 IU/ml for both TELCeB/AL-7 and TELCeB/MOF-1 cell lines.
Infection of NIH3T3 cells to determine amphiphile effects on transduction NIH3T3 cells were seeded into 12-well dishes at 5 × 10 4 cells per well and left overnight at 37°C. Virosome complexes were prepared by mixing an appropriate concentration of cationic agent with 20 l of virus stock in a total of 0.5 ml of serum-free DMEM. After 45-min incubation, the volume of medium was made up to 3 ml with DMEM containing FCS to bring the serum concentration to 10%. The medium from each well was replaced with the appropriate virosome complex and the cells were left for 24 h. The following day the virosome complexes were removed from the wells and the cells were washed with PBS and refed with fresh serum containing medium. The cells were left for a further 24 h to allow transgene expression. Each well was then washed in PBS and trypsinised. Using virus produced by GPE+86 LHL and PA317 tgLS[+]HyTK cells, NIH3T3 cells were diluted 1/50 on to 60-mm dishes in hygromycin B (Calbiochem) selection at 500 U/ml and left to grow for 7-10 days after which time colonies were scored following methylene blue staining. NIH3T3 cells infected by virus from TELCeB/AL-7 and TELCeB/MOF-1 cell lines were examined using a ␤-galactosidase assay. High titre virus was also tested on the HepG2 liver cancer cell line using the amphotropic/cationic agent complexes which gave optimum virus titres on NIH3T3 cells.
Cationic agents
The cationic agents used in this study are as follows: In vivo transduction of rat liver with retrovirus Male Wistar rats weighing 200-250 g were used. They were housed in a temperature-and light-controlled room (12 h light/ dark cycle) and were allowed water and food ad libitum.
For in vivo transduction, a modified method of Rettinger et al 18 was used: 24 h following partial hepatectomy the animal was anaesthetised with isoflurane anaesthetic (Abbott Laboratories, Kent, UK), a mid-line laparotomy was performed, the bowel was deflected to the left and wrapped in normal saline soaked gauze. The portal vein and hepatic artery were clamped using microaneurysm clips, the portal vein was cannulated with a 26-gauge needle and 2 ml of retroviral supernatant either with or without the addition of cationic agent at the concentration used in vitro was injected over 5 min. Haemostasis was achieved by direct pressure to the portal vein and topical thrombin (Sigma) application. The clips were removed and the abdomen sutured, and animals were allowed to recover in a warm environment. On day 11, animals were anaesthetised using Hypnorm (Janssen, High Wycombe, UK) and Hypnovel (Roche, Welwyn Garden City, UK) and killed by exsanguination. Tissue from the liver, testes, heart, lung, skeletal and brain was fresh frozen in liquid nitrogen.
Histological processing and analysis
To analyse the tissue expression of the ␤-galactosidase transgene, 10 m frozen sections were cut on to glass slides, fixed in a solution of 1.25% glutaraldehyde at 4°C, washed with PBS, covered in X-gal (5-bromo-4-chloro3indolyl-␤-d-galactosidase; GibcoBRL) solution (pH 7.4) and incubated overnight at 37°C. Sections were then washed in PBS, counterstained lightly with eosin or carmalum stain, dehydrated and mounted in pertex (Cellpath, Hemel Hempstead, UK). The proportion of hepatocytes expressing nuclear localised ␤-galatosidase was calculated by counting 2000 hepatocytes per section from three separate areas. The specificity of staining was confirmed by examining serial sections.
Analysis of in vitro and in vivo toxicity of the cationic agents In vitro analysis of the cytotoxic effects of retroviruses complexed with cationic agents on NIH3T3 cells was performed both morphologically and by clonal assay. Infected cells and control mock-infected cells were seeded at clonal density on to 60-mm dishes at 100 cells per dish. Colonies of cells either in the presence or absence of selective agent were scored and compared with unselected mock-treated cells.
Following in vivo administration of the retroviral/cationic agents to both normal animals and animals which had received a partial hepatectomy 24 h earlier, the animals were observed for signs of distress. At the time of death (day 11) histological sections of the liver were examined for either ongoing hepatitis or evidence of recent hepatocyte necrosis.
